MODIFIED EPITOPES FOR BOOSTING CD4+ T-CELL RESPONSES

The present invention relates to immunogenic peptides comprising a T-cell epitope. Said peptides are modified such that CD4+ T-cell responses are obtainable that are much stronger than the CD4+ T-cell responses obtained with the same peptides not comprising said modification. In particular, the modification is the addition of a cysteine, insertion of a cysteine or mutation into a cysteine of a residue at a position adjacent to but outside the MHC-binding site of the peptide. Further disclosed are the use of such modified peptides in treating, suppressing or preventing diseases such as infectious or allergic diseases and autoimmune diseases, in preventing or suppressing graft rejection, or in the eradication of tumor cells.

Patent Publication Number: EP2809332

Year filing: 2013

Year approval: 2015

Year publication: 2014

Status: Requested

Technology domains: Pharmaceuticals

Validated for IOF-key: Yes

Attributed to: Associatie KULeuven